RightFit
RecruitingPhase not listed

Home-based Oral Glucose Tolerance Test for Type 1 Diabetes Screening

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
8 Years to 45 Years
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study tests how accurate a home fingerstick blood sugar test is compared with blood drawn from a vein at a clinic. It is for people at risk for type 1 diabetes or diagnosed with it within the past 100 days.

This study aims at quantifying the accuracy of a self-administered fingerstick based glucose tolerance test (GTT@Home) respect to the gold-standard in-clinic venous plasma measures during the oral glucose tolerance test (OGTT) across a wide range of glycemic values in people at risk for clinical type 1 diabetes (T1D) (carriers of at least one islet autoantibody) or with new onset Stage 3 T1D within 100 days from the diagnosis.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Weigh at least 43 kg (about 95 pounds).
  • Have a record showing at least one islet autoantibody—a sign that the immune system may attack cells that make insulin.
  • If you have stage 3 type 1 diabetes, join within 100 days of diagnosis and be at least 12 years old.
  • Be in good general health, with no other illness that the study doctor thinks could make the study unsafe or affect its results.
  • Be able to give consent or assent, meaning agreement to take part.
  • Be able to understand written and spoken English.

Who can't join

  • Are pregnant or become pregnant during the study.
  • Take an SGLT inhibitor, a type of medicine that lowers blood sugar.
  • Have donated blood in the past 8 weeks.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * Body weight ≥43 kg * Presence of at least one islet autoantibody and/or≥ diagnosis of clinical T1D within 100 days. * Documentation of the presence at least 1 islet autoantibody * If participants meet ADA diagnostic criteria for Stage 3 type 1 diabetes, they will be eligible if the enrollment occurs within 100 days from the diagnosis and are at least 12 years old. * Participants must be in good general health without other acute (e.g. infectious disease) febrile or chronic illnesses (e.g. uncontrolled asthma requiring high steroid doses, chronic arthritis) that in the judgment of the investigator could jeopardize participant safety or interfere with the study, * Ability to give consent/assent * Able to understand written and spoken English Exclusion Criteria: * Currently pregnant or becomes pregnant during the study * Participants on sodium glucose cotransporter inhibitors (SGLTi). * Donated blood in the past 8 weeks.

Study sites (1)

CT